The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Daratumumab in AL Amyloidosis: Frontline and Relapsed Management

Anti-CD38 monoclonal antibody for systemic light chain amyloidosis

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Daratumumab in AL Amyloidosis: Frontline and Relapsed Management?

Systemic AL amyloidosis is caused by clonal plasma cells producing misfolded immunoglobulin light chains that deposit in organs.

Daratumumab targets CD38 on clonal plasma cells, depleting them and reducing pathological light chain production.

Subcutaneous daratumumab faspro plus cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) is frontline standard.

ANDROMEDA trial showed superior hematologic complete response and organ response rates compared to CyBorD alone.

Used in relapsed disease either as monotherapy or combined with proteasome inhibitors and immunomodulators.

Symptoms

Infusion or injection-related reactions: fever, chills, dyspnea more common with intravenous formulation.
Cytopenias: neutropenia and thrombocytopenia related to plasma cell depletion.
Cardiac symptoms in patients with cardiac amyloidosis require careful monitoring during therapy.
Renal manifestations include proteinuria and worsening kidney function in advanced disease.
Peripheral neuropathy from concurrent bortezomib administration.

Risk Factors

Cardiac involvement (Mayo stage III) increases treatment-related mortality risk.
Severe renal dysfunction limits cyclophosphamide tolerance.
Autonomic neuropathy with orthostatic hypotension complicates dosing.
Hepatic amyloidosis with elevated alkaline phosphatase or coagulopathy.
Advanced age and frailty influence treatment intensity decisions.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Worsening dyspnea, edema, or syncope suggesting cardiac progression.
  • New or worsening neuropathy interfering with daily activities.
  • Significant proteinuria increase or rising creatinine.
  • Persistent infusion-related reactions despite premedication.
  • Signs of severe infection: high fever, hypotension, or altered mental status.

Treatment Methods

01
Dara-CyBorD frontline: subcutaneous daratumumab faspro 1800 mg weekly, then biweekly, with weekly oral cyclophosphamide, bortezomib, and dexamethasone.
02
Premedication: corticosteroids, antihistamines, and antipyretics for first doses to mitigate reactions.
03
Cardiac monitoring with NT-proBNP and troponin trends during therapy.
04
Daily dexamethasone schedule based on cardiac stage to balance efficacy and toxicity.
05
Maintenance daratumumab monotherapy continues for up to 24 cycles or until progression in responders.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.